News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Announces Launch of Antiepileptic Drug Fycompa In U.S.



1/30/2014 4:45:42 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tokyo, Jan 6, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that on January 2, 2014, its U.S. subsidiary Eisai Inc. launched the AMPA receptor antagonist Fycompa (perampanel), a first-in-class antiepileptic drug (AED) discovered and developed In-house, in the United States as an adjunctive therapy for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 and older.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES